IN2014KN02335A - - Google Patents

Info

Publication number
IN2014KN02335A
IN2014KN02335A IN2335KON2014A IN2014KN02335A IN 2014KN02335 A IN2014KN02335 A IN 2014KN02335A IN 2335KON2014 A IN2335KON2014 A IN 2335KON2014A IN 2014KN02335 A IN2014KN02335 A IN 2014KN02335A
Authority
IN
India
Prior art keywords
patient
risk
reducing
acting insulin
therapeutically effective
Prior art date
Application number
Inventor
Peter Johnston
Hertzel Gerstein
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of IN2014KN02335A publication Critical patent/IN2014KN02335A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention relates to the use of use of a long-acting insulin, in particular insulin glargine, in a method of reducing the risk of progression to type 2 diabetes in a patient, a method of reducing the risk of a new angina in a patient and a method of reducing the risk of a microvascular event in a patient comprising administering to said patient in need thereof a therapeutically effective dosage of a long acting insulin, wherein said therapeutically effective dosage of said long acting insulin reduces said risks.
IN2335KON2014 2012-03-28 2013-03-28 IN2014KN02335A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261616768P 2012-03-28 2012-03-28
US201261619641P 2012-04-03 2012-04-03
US201261624598P 2012-04-16 2012-04-16
US201261645909P 2012-05-11 2012-05-11
US201261701911P 2012-09-17 2012-09-17
PCT/EP2013/056661 WO2013144273A1 (en) 2012-03-28 2013-03-28 Basal insulin therapy

Publications (1)

Publication Number Publication Date
IN2014KN02335A true IN2014KN02335A (en) 2015-05-01

Family

ID=48044781

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2335KON2014 IN2014KN02335A (en) 2012-03-28 2013-03-28

Country Status (13)

Country Link
US (1) US20150065421A1 (en)
EP (1) EP2830650A1 (en)
JP (1) JP2015512908A (en)
KR (1) KR20150001757A (en)
CN (1) CN104334183A (en)
AU (1) AU2013241776B2 (en)
CA (1) CA2865823A1 (en)
HK (1) HK1201155A1 (en)
IN (1) IN2014KN02335A (en)
MX (1) MX2014011687A (en)
RU (1) RU2014143271A (en)
SG (1) SG11201405433XA (en)
WO (1) WO2013144273A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017108943A1 (en) * 2015-12-23 2017-06-29 Sanofi-Aventis Deutschland Gmbh Cardiac metabolic effect of lantus
MA46897A (en) 2016-11-28 2021-04-28 Novo Nordisk As INSULIN DEGLUDEC USED IN CARDIOVASCULAR CONDITIONS
WO2018096164A1 (en) * 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for treating diabetes
WO2018096163A1 (en) * 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for improvement of glycaemic control and reduction of acute and long-term diabetes complications

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0309154D0 (en) * 2003-01-14 2003-05-28 Aventis Pharma Inc Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia
BR112012032579B1 (en) * 2010-06-24 2021-05-11 Boehringer Ingelheim International Gmbh use of linagliptin and pharmaceutical composition comprising linagliptin and long-acting basal insulin

Also Published As

Publication number Publication date
EP2830650A1 (en) 2015-02-04
MX2014011687A (en) 2015-05-11
CA2865823A1 (en) 2013-10-03
AU2013241776B2 (en) 2017-11-02
AU2013241776A1 (en) 2014-10-16
RU2014143271A (en) 2016-05-20
KR20150001757A (en) 2015-01-06
US20150065421A1 (en) 2015-03-05
CN104334183A (en) 2015-02-04
JP2015512908A (en) 2015-04-30
WO2013144273A1 (en) 2013-10-03
HK1201155A1 (en) 2015-08-28
SG11201405433XA (en) 2014-10-30

Similar Documents

Publication Publication Date Title
MY167234A (en) Novel glucagon analogues
CL2013003454A1 (en) Pharmaceutical composition for preventing or treating diabetes comprising a long-acting insulin conjugate and a long-acting insulinotropic peptide conjugate.
MX2020010693A (en) Use of long-acting glp-1 peptides.
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
PH12014501702A1 (en) Imidazopyrrolidinone compounds
PH12014501561A1 (en) Therapeutically active compounds and their methods of use
IL227623B (en) Nanoparticle compositions comprising a population of particles, for use in the manufacture of a topical medicament for treating a subject suffering from or susceptible to a condition or disorder associated with sweat glands and/or sebaceous glands
MX2013011175A (en) Novel glucagon analogues.
EA201590058A1 (en) ANALOGUE GLUACAGONA
EA201991014A1 (en) DIABETES TREATMENT
MX356728B (en) Pharmaceutical combination for use in the treatment of diabetes type 2.
MX366090B (en) Pharmaceutical combination for use in inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients.
MX363507B (en) Methods of administering nitric oxide to arterial or arterialized blood.
WO2014153385A3 (en) Methods of treating metabolic disorders
IN2014KN02335A (en)
MX2016007682A (en) Pharmaceutical composition comprising amorphous ivabradine.
WO2013083826A3 (en) Glp-1 agonists
WO2014018763A3 (en) Method of treating type i diabetes using apolipoprotein aiv
MX2014006990A (en) Treatment of type i and type ii diabetes.
PH12014502497A1 (en) New treatments of hepatitis c virus infection
UA111785C2 (en) A COMPOSITION FOR THE TREATMENT OF Warts And A WAY OF TREATMENT
GB201217635D0 (en) Use of short term insulin treatment to restore pancreatic function in type 2 diabetic patients who have become refractory through oral hypolgycaemic agents
MX2019008148A (en) Use of long-acting glp-1 peptides.
UA79052U (en) method for immunotherapy in exacerbations of chronic bronchitis in patients with insulin resistance
MX368505B (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan- 1-aminium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes.